Abstract Advanced melanoma presents a significant therapeutic challenge to clinicians. Many therapies for metastatic melanoma are limited by low response rates, severe toxicities, and/or relatively short response duration. Cancer immunotherapies that act as immune-checkpoint inhibitors to block the localized immune suppression mechanisms utilized by tumors are undergoing development and clinical trials. A clinically relevant immune escape mechanism in melanoma is the activation of the programmed cell death-1 (PD-1) receptor on infiltrating T cells. Activating PD-1 triggers an immune checkpoint resulting in inhibition of T cells directed against melanoma antigens and prevents the immune system from combating the melanoma. In Phase I clinical trials, two anti-PD1 therapies, Nivolumab and MK-3475, that block the PD-1 receptor to enable T cell killing have demonstrated objective tumor responses in patients with advanced melanoma. The purpose of this review is to present the available clinical evidence on anti-PD-1 and anti-PD-L1 immunotherapy for the treatment of advanced melanoma. We also discuss limitations associated with anti-PD-1 therapy. The blockade of the PD-1-PD-L1 pathway has shown promising results in clinical trials and has revolutionized melanoma immunotherapy.
Introduction
In 2014, it is estimated melanoma will contribute to 76,100 new cancer diagnoses and 9,710 deaths in the United States [29] . Advanced melanoma presents a significant therapeutic challenge to clinicians. Many therapies for metastatic melanoma are limited by low response rates, severe toxicities, and/or relatively short response duration [11] . Historically, treatment for advanced melanoma involved the use of cytotoxic therapies, such as dacarbazine, that have response rates of approximately 10-15 % and caused dose-limiting toxicities [11, 20] . The cytokine interleukin-2 (IL-2) is also used to treat advanced melanoma, however, the response rate is only 6-10 % and it too is associated with significant toxicities. Newer oncologic treatments for melanoma include targeted therapies, such as kinase inhibitors that are now a mainstay treatment for melanomas that harbor key mutations contributing to melanoma pathogenesis, such as BRAF [20] .
BRAF mutations are present in 40-60 % of melanoma patients and these mutations lead to the activation of kinase activity [5, 7, 8, 11] . Inhibitors of these BRAF mutations, such as vemurafenib and dabrafenib, have shown response rates of 48-53 % and have revolutionized melanoma treatment, but are limited to treating melanomas that harbor a BRAF mutation [5, 7, 8, 11] . Additionally, the majority of patients treated with BRAF inhibitors go on to relapse within 6-12 months.
In addition to key mutations such as BRAF, human cancers harbor antigens that allow a patient's immune system to recognize and mount an endogenous immune response against the tumor [23, 27, 28] . However, endogenous anti-tumor immune responses are often ineffective because tumors can activate key immune checkpoints that lead to localized immune suppression [9, 14, 15, 23, 33] . Cancer immunotherapies that act as immune-checkpoint inhibitors to block the localized immune suppression mechanisms utilized by tumors are undergoing development and being put to test in clinical trials [19] .
The first immunotherapy approved for the treatment of advanced melanoma was ipilimumab, a monoclonal antibody (mAb) that targets cytotoxic T-lymphocyte antigen-4 (CTLA-4) and prevents a distinct mechanism of immune suppression that involves CTLA-4 [21] . Ipilimumab has demonstrated improved overall survival in patients with previously treated metastatic melanoma [10, 18] . Most recently, immunotherapies targeting another clinically relevant mechanism of immune suppression involving the immune-checkpoint PD-1 receptor and its ligand, PD-L1, are undergoing clinical trials for the treatment of advanced melanoma (Table 1) [24] . Two drugs that bind to PD-1 and block the interaction of the receptor with its ligand to enable T cell killing are nivolumab (MDX-1106 or BMS-936558, Bristol-Myers Squibb) and MK-3475 (Merck). Nivolumab and MK-3475 have demonstrated durable objective clinical response per the RECIST 1.1 criteria in melanoma tumor size in phase I clinical trials and may have the potential to change the treatment paradigm for advanced melanoma [24] .
The PD-1 receptor acts as an immune checkpoint by terminating or inhibiting the immune response through T cell activity downregulation and induction of tolerance to antigens [6, 13] . When PD-1 is unbound, T cells are free to react against target cells; when PD-1 is bound to ligand, it suppresses the immune response of T cells (Fig. 1a) [38] . The PD-1 immune checkpoint is believed to normally play a role in ensuring self-tolerance to prevent autoimmunity. However, translational research indicates that interferon gamma, secreted by tumor-infiltrating cytotoxic T cells, leads to an upregulation of PD-L1 on the surface of melanoma cells that activates the PD-1 receptor to prevent immune recognition and destruction of melanoma cells. By blocking PD-1 receptors with anti-PD-1 mAbs, T cells are unaffected by the PD-L1 expressed on tumor cells and the patient's T cells are free to respond to melanoma antigens and attack tumor cells (Fig. 1b) . This new class of immunotherapy, based on anti-PD1, is now a validated strategy based on efficacy results in Phase I trials, irrespective of mutation type or previous treatments.
Methods
We employed the following search strategy to identify the clinical evidence reported in the biomedical literature: in January 2014, we searched Medline, PubMed, EMBASE, and ClinicalTrials.gov (January 1990-present) using the following search terms:
All clinical trials evaluating anti-PD-1 or anti-PD-L1 therapy for the treatment of melanoma were included.
Results
Our search identified five clinical trials meeting inclusion criteria for evaluating anti-PD-1 therapy for melanoma. A detailed list of the included clinical trials is presented in Table 2 and 3.
Discussion
Anti-PD-1 monotherapy Our review of the literature demonstrates that nivolumab is a promising treatment for patients with advanced melanoma. One phase I trial conducted by Brahmer et al. investigated the safety, tolerability, and anti-tumor activity of nivolumab in 39 patients with either treatment-refractory advanced melanoma, colorectal cancer (CRC), castrateresistant prostate cancer, non-small cell lung cancer, or renal cell carcinoma (RCC) [4] . This early study found 1 out of 10 patients with melanoma treated with nivolumab experienced a partial response to therapy, as measured by a reduction in tumor size using the RECIST 1.1 [4] .
Investigators also reported another partial response in a patient with RCC and one complete response in CRC [4] . Since only 31 % (12/39) of patients received multiple doses of nivolumab, interpretation of the reported response rates is limited because many patients may not have responded due to an ineffective dose [4] . Investigators reported no dose-limiting toxicities; however, they report a drug-related episode of grade 3 inflammatory colitis and an episode of grade 2 hypothyroidism in another patient. These immune-related adverse events are of particular interest in anti-PD-1 trials and are similar to those seen in ipilimumab trials [3, 22] . Immune-related adverse events are likely a critical dose-limiting toxicity of PD-1 inhibitors.
Another phase I trial investigating the use of nivolumab for the treatment of a variety of solid tumors reported 28 % (26/94) of patients with advanced melanoma who had melanoma progression while on previous tumor therapies showed an objective response to treatment after receiving nivolumab at a dose of 0.1-10.0 mg/kg of body weight every 2 weeks over an 8-week cycle period. In addition, objective responses were observed in 41 % (7/17) of patients receiving nivolumab at a dose of 3 mg/kg. Patients received treatment for up to 12 cycles until disease progression was noted or complete response occurred [31] . This study also reported similar objective response rates in patients with renal cell carcinoma and non-small cell lung cancer. In addition, 72 % (13/18) of patients who responded to nivolumab treatment with adequate follow-up had responses lasting 1 year or longer [31] . The investigators found that drug-related grade 3 or 4 toxic effects occurred in 14 % (41/296) of patients with advanced melanoma, renal cell cancer, or non-small cell lung cancer [31] . This study also assessed the role of tumoral PD-L1 expression on treatment response and found that 36 % (9/25) of patients with PD-L1-positive tumors had an objective response, while no patients with PD-L1-negative tumors had an objective response [31] . However, due to the limited patient sample size, conclusions regarding the predictive power of PD-L1 expression are difficult to make. Preliminary results from another clinical trial investigating the use nivolumab with or without a multi-peptide vaccine reported nivolumab response rates by RECIST were 28 % in 34 patients who were naïve to ipilimumab, and 32 % in 46 patients who had failed prior ipilimumab therapy [34] .
A phase I trial of the anti-PD-1 antibody MK-3475 included 135 patients with advanced melanoma. The trial demonstrated an overall objective response of 38 % (44/ 117) and an objective response of 52 % (27/52) in patients receiving the maximum dose of 10 mg/kg every 2 weeks [17] . The authors report that 13 % (17/135) of patients experienced grade 3 or 4 toxicities. In addition, they report that prior exposure to ipilimumab or IL-2, did not appear to Arch Dermatol Res (2014) 306:511-519 513 have a major effect on response to MK-3475 treatment [17] . Taken together, the promising response rates from these phase I monotherapy trials demonstrate that anti-PD-1 mAbs have the potential to alter the melanoma treatment paradigm. Anti-PD-1 mAbs are associated with adverse events, including immune-related events. However, the results of nivolumab and MK-3475 indicate that as the immunotherapy drug class continues to expand, PD-1 inhibitors will be an effective therapy to combat advanced. In addition, further research to identify biomarkers beyond PD-L1 tumor expression, may allow clinicians to identify patients who are most likely to respond to anti-PD-1 therapy while minimizing adverse events. Merck has begun a phase III clinical trial comparing MK-3475 against ipilimumab in patients with advanced melanoma.
Immune checkpoint combination therapies
Combining multiple immune checkpoint blocker therapies has demonstrated beneficial results for the treatment of advanced melanoma. One recent clinical trial showed nivolumab combined with ipilimumab resulted in greater response rates than monotherapy with either drug [37] . Fifty-three patients received concurrent therapy with nivolumab and ipilimumab, and 33 received sequenced treatment (nivolumab administered within 4-12 weeks following last ipilimumab dose) [37] . The authors report that 53 % of patients who received combination therapy with nivolumab 1 mg/kg and ipilimumab 3 mg/kg had an objective response versus only 20 % of patients who received the sequential treatment. All responders had tumor reductions of 80 % or more [37] . The trial observed Grade 3 or 4 adverse events occurred in 53 % of patients in the concurrent-regimen group, and in 18 % of patients in the sequenced-regimen group. This study illustrated that concurrent therapy with nivolumab and ipilimumab may act synergistically and result in improved response rate versus monotherapy while maintaining a manageable rate of adverse events [37] . In addition, the authors reported that concurrent nivolumab plus ipilimumab therapy resulted in objective response in both patients with PD-L1-positive tumors (6/13) and with PD-L1-negative tumors (9/ 22). The effectiveness of nivolumab on PD-1-negative tumors is uncertain, further evaluation of tumor PD-L1 expression in clinical trials may clarify PD-1's utility as a biomarker for response rate to mono and combination therapy.
These promising synergistic findings have resulted in a phase III clinical trial to further investigate the utility of nivolumab plus ipilimumab combination therapy for the treatment of melanoma. Other combinations of nivolumab with existing or newly developed therapies for melanoma may provide enhanced survival benefit and decreased immunotherapy-related adverse effects. In addition, future Phase III trials will likely elucidate further details regarding the safety and effectiveness of PD-1 inhibitors alone and in combination with existing melanoma chemotherapeutics.
Anti-PD-L1 therapy
In addition to mAbs targeting the PD-1 receptor, mAbs have also been developed that target PD-L1. A phase I trial of the anti-PD-L1 antibody BMS-936559 reported objective responses to therapy in 17 % (9/52) of patients with melanoma [31] . The trial also demonstrated prolonged stabilization of disease in 27 % (14/52) of patients assessed 24 weeks after beginning therapy [31] . The investigators found that 39 % (81/207) of patients experienced immunerelated adverse events of any grade [31] . This study also assessed the median anti-PD-1 receptor occupancy in [17] . Further studies on the efficacy of anti-PD-L1 therapies are forthcoming and we anticipate that combination therapies may prove to be a promising option when utilizing anti-PD-L1.
Limitations and future directions
Similar to other cancer therapies, nivolumab treatment is commonly associated with adverse events that include fatigue, decreased appetite, diarrhea, nausea, cough, dyspnea, constipation, vomiting, dermatitis, pyrexia, and headache [31] . Additional immune-related adverse events include pneumonitis, vitiligo, colitis, hepatitis, hypophysitis, and thyroiditis [31] . These immune-related adverse events may prove to be a limitation of PD-1 inhibitors for some patients; however, adverse events are less frequent and severe than with ipilimumab and most patients who discontinue due to toxicity still have durable and ongoing response [30] . Larger studies may reveal how to best manage immune-related adverse events when taking immunotherapy anti-PD-1 mAbs without limiting clinical efficacy.
Due to the cost of immunotherapy, chance of adverse events, and heterogeneity of individual tumors, it is important for clinicians and researchers to be able to predict a patient's likelihood of response and adverse events. One method is to utilize biomarkers to predict likelihood of response to stratify patients prior to therapy. Initial data on nivolumab showed that 36 % (9 out of 25) of patients with PD-L1-positive tumors responded to therapy and 0 out of 17 patients with PD-L1-negative tumors responded to therapy [31] . Reports at ASCO 2013 have suggested that PD-L1 detected in biopsy samples by immunohistochemistry may be capable of predicting activity of nivolumab in advanced cancer [16, 35] . In addition, a recent study noted that PD-L1 tumor expression and T cell gene signature correlated with responses to MPDL3280A [26] . However, data presented at the annual 2013 ASCO conference have also reported objective responses to nivolumab in patients with PD-L1-negative tumors [32] . This may be due to heterogenous tumor expression of PD-1, thus making a single negative biopsy insufficient to determine if a tumor is truly PD-L1 negative. Further randomized clinical trials are needed to evaluate the utility of PD-L1 as biomarker for patient selection.
Given the uncertainty of predictions based on PD-L1 expression or any other single biomarker, clinicians may choose to utilize a panel of specific biomarkers that can accurately predict and stratify patients based on their likelihood of response, should a useful biomarker panel become available [1, 2] . The use of biomarkers to profile immune cells that have infiltrated a tumor may also prove valuable to clinicians [1] . These profiling tools could be used to understand the dynamic state of the immune system in the individual tumor and tailor immunotherapy selection accordingly.
In addition, translational research on serial tumor biopsies from patients treated with BRAF-inhibitors has demonstrated that BRAF inhibition is associated with an increase in melanoma antigen expression and T cell infiltrate, and a decrease in immunosuppressive cytokines in tumors of treated patients [12, 36] . These findings suggest that BRAF inhibitors may work synergistically with immunotherapy agents such as PD-1 inhibitors. Clinical trials that are currently in progress investigate combining BRAF-targeted therapy and immunotherapy for the treatment of advanced melanoma.
Although the results of the phase I clinical trials are impressive, it remains to be seen if PD-1 inhibitors demonstrate improved patient survival in phase III trials. In addition, because immunotherapies require time for induction of an immune response, they take longer to show an effect compared to cytotoxic or targeted therapies. Due to this delay, immunotherapies have been reported to cause transient progression in disease prior to objective reductions in tumor size [25] . Therefore, phase I trials may underestimate the actual response rate to immunotherapy using objective response measurements that capture transient progression in disease prior to reductions in tumor size [25] . As new immunotherapies are developed, we anticipate additional targets involved in the PD-1-PD-L1 signaling pathway, as well as additional pathways related to tumor immune suppression, will likely emerge.
Conclusion
The treatment of advanced melanoma is evolving as exciting new drugs that inhibit immune checkpoints are developed. These immune-checkpoint inhibitors allow a patient's endogenous immune response to assist in combating advanced melanoma or other types of cancer. Nivolumab alone and in combination with ipilimumab has been shown to be effective in the treatment of advanced melanoma. Moving forward, there is a need to develop biomarkers to predict response to anti-PD-1 mAbs and Arch Dermatol Res (2014) 306:511-519 517 design strategies to manage and avoid adverse immunerelated events. We anticipate that as immunotherapies continue to develop, additional targets involved in the PD-1-PD-L1 signaling pathway, as well as additional related immunotherapy pathways, will likely emerge. The use of antibodies targeting the PD-1-PD-L1 pathway, in combination with existing and new immunotherapies, has the potential to alter the current melanoma treatment paradigm and usher in an exciting new era of advanced melanoma treatment with improved patient outcomes.
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